Literature DB >> 3481327

Biliary tract excretion of ofloxacin in man.

A Kazmierczak1, A Pechinot, J M Duez, O Haas, J P Favre.   

Abstract

This study examined the biliary tract excretion of ofloxacin in 6 post-cholecystectomy patients with a T-tube inserted into the common duct (group A) and 6 patients during cholecystectomy (group B). The patients were given 7 oral doses of ofloxacin 200mg with a 12-hour interval between each dose. Blood and common duct bile samples were collected in group A at various time intervals after the first and the seventh dose. Blood, gallbladder wall, and gallbladder and common duct bile were collected in group B during operation, 6 hours after the seventh dose. Assays were performed by use of high performance liquid chromatography (HPLC). In group A, mean serum Cmax and half-life were 2.6 mg/L and 7.6 hours after the first dose, and 5.3 mg/L and 8 hours after the seventh dose, respectively. Mean common duct bile Cmax and half-life were 6.5 mg/L and 7.5 hours after the first dose, and 12.0 mg/L and 14 hours after the seventh dose, respectively. In group B, mean concentrations (mg/L) were 2.6 in blood, 5.3 in gallbladder wall, 24.6 in gallbladder bile and 10.1 in common duct bile, 6 hours after the seventh dose. These data suggest that ofloxacin may be suitable for the treatment of biliary tract infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481327     DOI: 10.2165/00003495-198700341-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  1 in total

1.  [Tissue concentration and effectiveness of ofloxacin in surgical patients].

Authors:  W Düben; A Student; M Jablonski; R Malottke
Journal:  Infection       Date:  1986       Impact factor: 3.553

  1 in total
  6 in total

Review 1.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 2.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

3.  Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.

Authors:  W L Hayton; V Vlahov; N Bacracheva; I Viachki; R Portmann; G Muirhead; K Stoeckel; E Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 4.  Fluoroquinolones and surgical prophylaxis.

Authors:  P Dellamonica; E Bernard
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  Penetration of ciprofloxacin and fleroxacin into biliary tract.

Authors:  C E Edmiston; E C Suarez; A P Walker; M P Demeure; C T Frantzides; W J Schulte; S D Wilson
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 6.  Quinolones and the gastrointestinal tract.

Authors:  B E Murray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.